Combining trastuzumab (Herceptin®) with hormonal therapy in breast cancer: What can be expected and why?

Annals of Oncology

Volumn 14, Issue 12, 2003, Pages 1697-1704

  Jones, Alison ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Anastrozole; Breast cancer; Estrogen receptor; HER2; Letrozole; Tamoxifen; Trastuzumab

Indexed keywords

ANASTROZOLE; ANDROGEN; ANTHRACYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; EXEMESTANE; FADROZOLE; FULVESTRANT; GESTAGEN; LETROZOLE; MEGESTROL ACETATE; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; RALOXIFENE; TAMOXIFEN; TOREMIFENE; TRASTUZUMAB;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER PATIENT; CARDIOTOXICITY; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG EFFICACY; DRUG INHIBITION; DRUG TOLERABILITY; GENE OVEREXPRESSION; HORMONAL THERAPY; HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION;

EID: 0346338203     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdg483     Document Type: Review

References (80)

1. Jordan C. Historical perspective on hormonal therapy of advanced breast cancer. Clin Ther 2002; 24 (Suppl A): A3-A16.
2. Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet 1896: 2: 162-167.
3. Allen E, Doisy EA. An ovarian hormone: preliminary reports on its localization, extraction and partial purification and action in test animals. J Am Med Assoc 1923; 81: 810-821.
4. Jensen EV, Jacobson HI. Fate of steroidal estrogens in target tissues. In Pincus G, Vollmer EP (eds): Biological Activities of Steroids in Relation to Cancer. New York, NY: Academic Press 1962; 161-174.
5. Sledge GW Jr. Breast cancer in the clinic: treatments past, treatments future. J Mammary Gland Biol Neoplasia 2001; 6: 487-495.
6. Slamon D. Clark G, Wong SG et al. Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene. Science 1987; 235: 177-182.
7. Allred DC, Swanson PE. Testing for erbB-2 by immunohistochemistry in breast cancer. Am J Clin Pathol 2000; 113: 171-175.
8. Sliwkowski MX, Lofgren JA, Lewis GD et al. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol 1999; 26: 60-70.
9. HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 1992; 89: 4285-4289.
10. Cobleigh MA, Vogel CL, Tripathy D et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17: 2639-2648.
11. Slamon D, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that over-expresses HER2. N Engl J Med 2001; 344: 783-792.
12. De Laurentiis M, Arpino G, Massarelli E et al. HER2 as a predictive marker of resistance to endocrine treatment (ET) for advanced breast cancer (ABC): a metanalysis of published studies. Breast Cancer Res Treat 2002; 70: (Abstr 233).
13. Dowsett M. Overexpression of HER-2 as a resistance mechanism to hormonal therapy in breast cancer. Endocr Relat Cancer 2001; 8: 191-195.
14. Lipton A. Ali SM, Leitzel K et al. Elevated HER-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. J Clin Oncol 2OO2; 20: 1467-1472.
15. Osborne CK, Schiff R, Fuqua SAW et al. Estrogen receptor: current understanding of its activation and modulation. Clin Cancer Res 2001; 7 (Suppl): 4338s-4342s.
16. Bentrem DJ, Jordan VC. Role of antiestrogens and aromatase inhibitors in breast cancer treatment. Curr Opin Obstet Gynecol 2002; 14: 5-12.
17. MacGregor JI, Jordan VJ. Basic guide to the mechanisms of antiestrogen action. Pharmacol Rev 1998; 50: 151-196.
18. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer. Cochrane Database Systematic Reviews 2001: 1: CD000486.
19. Buzdar AU. Endocrine therapy in the treatment of metastatic breast cancer. Semin Oncol 2001; 28: 291-304.
20. Fisher P, Costantino JP, Wickerham DL et al. Tamoxifen for the prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 1998; 90: 1371-1388.
21. Howell A, DeFriend D, Robertson J et al. Response to a specific anti-estrogen (ICI 182780) in tamoxifen-resistant breast cancer. Lancet 1995; 345: 29-30.
22. Goss PE, Strasser K. Aromatase inhibitors in the treatment and prevention of breast cancer. J Clin Oncol 2001; 19: 881-884.
23. Mouridsen H, Gershanovich M, Sun Y et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001; 19: 2596-2606.
24. Cunnick GH, Mokbel K. Aromatase inhibitors. Curr Med Res Opin 2001; 17: 217-222.
25. The ATAC Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomized trial. Lancet 2002; 359: 2131-2139.
26. Buzdar A, on behalf of the ATAC Trialists' Group. The ATAC ('Arimidex'. Tamoxifen, Alone or in Combination) trial in postmenopausal women with early breast cancer - updated efficacy results based on a median follow-up of 47 months. Breast Cancer Res Treat 2002; 70: (Abstr 13).
27. Sainsbury, on behalf of the ATAC Trialists' Group. Beneficial side-effect profile of anastrozole compared with tamoxifen confirmed by additional 7 months old exposure data: a safety update from the 'Arimidex', Tamoxifen, Alone or in Combination (ATAC) trial. Breast Cancer Res Treat 2002; 70: (Abstr 633).
28. Sommer S, Fuqua S. Estrogen receptor and breast cancer. Semin Cancer Biol 2001; 11: 339-352.
29. Akiyama T, Sudo C, Ogawara H et al. The product of the c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science 1986; 232: 1644-1646.
30. Burden S, Yarden Y. Neuregulins and their receptors: a versatile signaling module in organogenesis and oncogenesis. Neuron 1997; 18: 847-855.
31. Pinkas-Kramarski R, Soussan L, Waterman H et al. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J 1996; 15: 2452-2467.
32. Lemmon MA, Schlessinger J. Regulation of signal transduction and signal diversity by receptor oligomerization. Trends Biochem Sci 1994; 19: 459-463.
33. Alroy I, Yarden Y. The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions. FEBS Lett 1997; 410: 83-86.
34. Mansour SJ, Matten WT, Hermann AS et al. Transformation of mammalian cells by constitutively active MAP kinase. Science 1994; 265: 966-970.
35. Carraway KL, Soltoff SP, Diamonti AJ et al. Heregulin stimulates mitogenesis and phosphatidylinositol-3 kinase in mouse fibroblasts transfected with erbB2/neu and erbB3. J Biol Chem 1995; 270: 7111-7116.
36. Muthuswamy SK, Siegel PM, Dankort DL et al. Mammary tumors expressing the neu proto-oncogene possess elevated c-Src tyrosine kinase activity. Mol Cell Biol 1994; 14: 735-743.
37. Hynes NE, Stern DF. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta 1994; 1198: 165-184.
38. Di Fiore PP, Pierce JH, Fleming TP et al. Overexpression of the human EGF receptor confers and EGF-dependent transformed phenotype to HIH 3T3 cells. Cell 1987; 51: 1063-1070.
39. Di Fiore PP, Pierce JH, Kraus MH et al. ErbB-2 is a potent oncogen when overexpressed in NIH/3T3 cells. Science 1987; 237: 178-182.
40. Hudziak RM, Schlessinger J, Ullrich A. Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of HIH 3T3 cells. Proc Natl Acad Sci USA 1987; 84: 7159-7163.
41. Slamon DJ, Godolphin W, Jones LA et al. Studies of the HER2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-712.
42. Cross M, Dexter TM. Growth factors in development, transformation, and tumorigenesis. Cell 1991; 64: 271-280.
43. Drebin JA, Link VC, Greene MI. Monoclonal antibodies reactive with distinct domains of the neu oncogene-encoded p185 molecule exert synergistic anti-tumour effects in vivo. Oncogene 1988; 2: 273-277.
44. Drebin JA, Link VC, Greene MI. Monoclonal antibodies specific for the neu oncogene product mediate anti-tumour effects in vivo. Oncogene 1988; 2: 387-394.
45. Vogel CL, Cobleigh MA, Tripathy D et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20: 719-726.
46. Baselga J. Herceptin® alone or in combination with chemotherapy for the treatment of HER2-positive metastatic breast cancer: pivotal trials. Oncology 2001; 61 (Suppl 2): 14-21.
47. Seidman A, Hudis C, Pierri MK et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002; 20: 1215-1221.
48. Read LD, Keith D Jr, Slamon DJ et al. Hormonal modulation of HER-2/neu proto-oncogene messenger ribonucleic acid and p185 protein expression in human breast cancer cell lines. Cancer Res 1990; 50: 3947-3954.
49. Dati C, Antoniotti S, Taverna D et al. Inhibition of c-erbB-2 oncogene expression by estrogens in human breast cancer cells. Oncogene 1990; 5: 1001-1006.
50. Antoniotti S, Maggiora P, Dati C et al. Tamoxifen upregulates c-erbB-2 transcription in oestrogen-responsive breast cancer cells in vitro. Eur J Cancer 1992; 28: 318-321.
51. Pietras RJ, Arboleda J, Reese DM et al. HER2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 1995; 10: 2435-2446.
52. Benz CC, Scott GK, Sarup JC et al. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells, transfected with HER2/neu. Breast Cancer Res Treat 1992; 24: 85-95.
53. Kato S, Endoh H, Masuhiro Y et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 1995; 270: 1491-1494.
54. Bunone G, Briand PA, Miksicek RJ et al. Activation of the unliganded estrogen receptor by EGF involves the MAPKinase pathway and direct phosphorylation. EMBO J 1996; 15: 2174-2183.
55. Chung YL, Shen ML, Yang SC et al. Resistance to tamoxifen-induced apoptosis is associated with direct interaction between HER2/neu and cell membrane estrogen receptor in breast cancer. Int J Cancer 2002; 97: 306-312.
56. Kurokawa H, Lenferink AE, Simpson JF et al. Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Res 2000; 60: 5887-5894.
57. Benshushan A, Brzezinski A. Hormonal manipulations and breast cancer. Obstet Gynecol Surv 2002; 57: 314-323.
58. Lee H, Jiang F, Wang Q et al. MEKKI activation of human estrogen receptor α and stimulation of the agonistic activity of 4-hydroxytamoxifen in endometrial and ovarian cancer cells. Mol Endocrinol 2000; 14: 1882-1896.
59. Kurokawa H, Arteaga CL. Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer. Clin Cancer Res 2001; 7 (Suppl 12): 4436s-4442s.
60. Giai M, Roagna R, Ponzone R et al. Prognostic and predictive relevance of c-erbB-2 and ras expression in node positive and negative breast cancer. Anticancer Res 1994; 14: 1441-1450.
61. Stal O, Borg A, Femo M et al. ErbB2 status and the benefit from two or five years of adjuvant tamoxifen in postmenopausal early stage breast cancer. Ann Oncol 2000; 11: 1545-1550.
62. Bianco AR, De Laurentiis M, Carlomagno C et al. HER2 overexpression predicts adjuvant tamoxifen (TAM) failure for early breast cancer (EBC): complete data at 20 yr of the Naples GUN randomized trial. Proc Am Soc Clin Oncol 2000; 19: 75a (Abstr 289).
63. Elledge RM, Green S, Ciocca D et al. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group study. Clin Cancer Res 1998; 4: 7-12.
64. Berry DA, Muss HB, Thor AD et al. HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node positive breast cancer. J Clin Oncol 2000; 18: 3471-3479.
65. Piccart MJ, Di Leo A, Hamilton A. HER2: a 'predictive factor' ready to use in the daily management of breast cancer patients? Eur J Cancer 2000; 36: 1755-1761.
66. Ellis MJ, Coop A, Singh B et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 2001; 19: 3808-3816.
67. Ali SM, Leitzel K, Demers L et al. Predictive factors and response to letrozole vs. tamoxifen. Breast Cancer Res Treat 2002; 76: S32 (Abstr 14).
68. Colomer R, Llombart A, Ramos M et al. Serum HER-2 ECD and the efficacy of letrozole in ER+/PR+ metastatic breast cancer: preliminary results of a prospective study. Breast Cancer Res Treat 2001; 69: 242 (Abstr 223).
69. Love RR, Ba Duc N, Havighurst TC et al. HER-2/neu overexpression and response to oophorectomy plus tamoxifen adjuvant therapy in estrogen receptor-positive premenopausal women with operable breast cancer. J Clin Oncol 2003; 21: 453-457.
70. Kunisue H, Kurebayashi J, Otsuki T et al. Anti-HER2 antibody enhances the growth inhibitor effect of anti-oestrogen on breast cancer cells expressing both oestrogen receptors and HER2. Br J Cancer 2000; 82: 46-51.
71. Witters LM, Kumar R, Chinchilli VM et al. Enhanced antiproliferative activity of the combination of tamoxifen plus HER2-neu antibody. Breast Cancer Res Treat 1997; 42: 1-5.
72. Bolton MG, Murphy M, Cobleigh M et al. on behalf of the Herceptin Multinational Investigator Study Group. Estrogen receptor (ER) status in the Herceptin® (trastuzumab) clinical trials: incidence and relation to clinical benefit. Proc Am Soc Clin Oncol 2001; 20: 44a (Abstr 172).
73. Nicholson BP. Ongoing and planned trials of hormonal therapy and trastuzumab. Semin Oncol 2000; 27 (Suppl 11): 33-37.
74. Assikis VJ, Buzdar A. Recent advances in aromatase inhibitor therapy for breast cancer. Semin Oncol 2002; 29 (Suppl 11): 120-128.
75. MacGregor JI, Jordan VJ. Basic guide to the mechanisms of antiestrogen action. Pharmacol Rev 1998; 50: 151-196.
76. Nicholson S, Wright C, Sainsbury JR et al. Epidermal growth factor receptor as a marker for poor prognosis in node-negative breast cancer patients: neu and tamoxifen failure. J Steroid Biochem Mol Biol 1990; 37: 811-814.
77. Wright C, Nicholson S, Angus B et al. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer 1992; 65: 118-121.
78. Leitzel K, Teramoto Y, Konrad K et al. Elevated serum c-erbB2 antigen levels and decreased response to hormone therapy of breast cancer. J Clin Oncol 1995; 13: 1129-1135.
79. Yamauchi H, O'Neill A, Gleman R et al. Prediction of response to anti-estrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER2/neu protein. J Clin Oncol 1997; 15: 2518-2525.
80. Houston SJ, Plunkett TA, Barnes DM et al. Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer. Br J Cancer 1999; 79: 1220-1226.